Long-Term Cardiovascular Risk Associated With Treatment of Attention-Deficit/Hyperactivity Disorder in Adults
Abstract
No abstract availableKeywords
Funding Information
- IMK Almene Fond
- Dagmar Marshalls Fond
- Snedkermester Sophus Jacobsen og Hustru Astrid Jacobsens Fond
- Helsefonden
- Marie og MB Richters Fond
This publication has 30 references indexed in Scilit:
- Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular DiseasesJAMA Psychiatry, 2024
- Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity DisorderJAMA Network Open, 2022
- Attention‐deficit/hyperactivity disorder as a risk factor for cardiovascular diseases: a nationwide population‐based cohort studyWorld Psychiatry, 2022
- On the estimation of average treatment effects with right‐censored time to event outcome and competing risksBiometrical Journal, 2020
- Updated European Consensus Statement on diagnosis and treatment of adult ADHDEuropean Psychiatry, 2018
- The Active Comparator, New User Study Design in Pharmacoepidemiology: Historical Foundations and Contemporary ApplicationCurrent Epidemiology Reports, 2015
- The Danish Civil Registration System as a tool in epidemiologyEuropean Journal of Epidemiology, 2014
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged AdultsJAMA, 2011
- Risk-Set Matching2009
- Tutorial in biostatistics: competing risks and multi‐state modelsStatistics in Medicine, 2006